Objectif Despite effective vaccines, hepatitis B virus (HBV) infection remains a major health problem with 2 billion people infected worldwide. Among them, 350 million are chronically infected, a major risk factor for development of hepatocellular carcinoma (HCC). A new and efficient treatment against chronic infection and HCC is strongly needed, and therefore it is important to understand HBV replication and persistence. In the absence of a good model, woodchuck infection with woodchuck hepatitis virus (WHV) is used as the preferred system to study disease and by homology, HBV nature. In the present proposal we intent to establish a robust WHV reverse genetic system to study the virus replication and pathogenesis. By utilizing this WHV reverse genetic system, we plan to introduce two new strategies to generate virus-attenuated vaccines that could infect and interfere with wild type virus replication. WHV core is a structural protein required for virus replication and growth. We are proposing to construct a core deficient recombinant WHV that could replicate in wild type WHV infected cells, interfering with wild type infection. A second strategy focuses on Hepatitis B virus X (HBx) and woodchuck hepatitis virus X (WHx) multifunctional proteins, which are required for optimal HBV and WHV replication and development of WHV derived HCC. We propose to create recombinant WHV with a mutant WHx protein that will interfere with full-length protein activities if they are co-expressed. As an initial approach to study virus replication, we will utilize woodchuck hepatocyte xenograft transplants in RAG-1 transgenic mice. Finally, woodchuck animal model will be challenged to test the efficacy of recombinant viruses replication and interference with chronic infection and suppress HBV derived HCC. Our ultimate goal is to develop novel effective molecular therapeutic tools that could be combined with other HBV/WHV antiviral strategies to suppress chronic HBV infection and HBV derived HCC. Champ scientifique medical and health scienceshealth sciencesinfectious diseasesDNA viruseshepatitis B Programme(s) FP7-PEOPLE - Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) Thème(s) FP7-PEOPLE-2009-RG - Marie Curie Action: "Reintegration Grants" Appel à propositions FP7-PEOPLE-2010-RG Voir d’autres projets de cet appel Régime de financement MC-IRG - International Re-integration Grants (IRG) Coordinateur FUNDACION PARA LA INVESTIGACION MEDICA APLICADA FIMA Contribution de l’UE € 100 000,00 Adresse AVENIDA DE PIO XII 55 31008 Pamplona Espagne Voir sur la carte Région Noreste Comunidad Foral de Navarra Navarra Type d’activité Research Organisations Contact administratif Ana Iglesias Garcia (Ms.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée